The management of schizophrenia: focus on extended-release quetiapine fumarate

References

• WeidenPJPreskornSHFahnestockPACarpenterDRossRDochertyJPTranslating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a RoadmapJ Clin Psychiatry200768Suppl 714817650057
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• ValensteinMGanoczyDMcCarthyJFMyraKHLeeTABlowFCAntipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective reviewJ Clin Psychiatry200667101542155017107245
   PubMed Web of Science ®Google Scholar
• VelliganDILamFEreshefskyLMillerALPsychopharmacology: perspectives on medication adherence and atypical antipsychotic medicationsPsychiatr Serv200354566566712719495
   PubMed Web of Science ®Google Scholar
• ByerlyMJNakoneznyPALescouflairEAntipsychotic medication adherence in schizophreniaPsychiatr Clin North Am200730343745217720031
   PubMed Web of Science ®Google Scholar
• GitlinMNuechterleinKSubotnikKLClinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophreniaAm J Psychiatry2001158111835184211691689
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLacroJPDolderCRA prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaJ Clin Psychiatry20066771114112316889456
   PubMed Web of Science ®Google Scholar
• LeuchtSHeresSEpidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophreniaJ Clin Psychiatry200667Suppl 53816822090
   PubMed Web of Science ®Google Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry200418434635115056580
   PubMed Web of Science ®Google Scholar
• WyattRJNeuroleptics and the natural course of schizophreniaSchizophr Bull19911723253511679255
   PubMed Web of Science ®Google Scholar
• MarcusSCOlfsonMOutpatient antipsychotic treatment and inpatient costs of schizophreniaSchizophr Bull200834117318017578893
   PubMed Web of Science ®Google Scholar
• FleischhackerWWHoferAHummerMManaging Schizophrenia: the compliance challengeCurrent Medicine Group2007
   Google Scholar
• HudsonTJOwenRRThrushCRA pilot study of barriers to medication adherence in schizophreniaJ Clin Psychiatry200465221121615003075
   PubMed Web of Science ®Google Scholar
• MasandPSNarasimhanMImproving adherence to antipsychotic pharmacotherapyCurr Clin Pharmacol200611475618666377
   PubMedGoogle Scholar
• JonsdottirHFriisSHorneRPettersenKIReikvamAAndreassenOABeliefs about medications: measurement and relationship to adherence in patients with severe mental disordersActa Psychiatr Scand20091191788418983630
   PubMed Web of Science ®Google Scholar
• TandonRMarcusRStockEA prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA)Schizophr Res2006841778916483745
   PubMed Web of Science ®Google Scholar
• KikkertMJScheneAHKoeterMWMedication adherence in schizophrenia: exploring patients’, carers’ and professionals’ viewsSchizophr Bull200632478679416887889
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHWeidenPJMcEvoyJPHamerRMLiebermanJAPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice guideline for the treatment of patients with schizophrenia [updated 2004] Available from: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2ePG_05-15-06. Accessed January 21, 2010.
   Google Scholar
• National Institute of Clinical ExcellenceCore interventions in the treatment and management of schizophrenia in primary and secondary care (Clinical Guideline 1) [updated 2004 Apr 12] Available from: http://www.nice.org.uk.
   Google Scholar
• TandonRJibsonMDExtrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcomeAnn Clin Psychiatry200214212312912238737
   PubMedGoogle Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
   PubMed Web of Science ®Google Scholar
• De HertMSchreursVSweersKTypical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart reviewSchizophr Res20081011–329530318299188
   PubMed Web of Science ®Google Scholar
• ArangoCBobesJManaging acute exacerbations of schizophrenia: focus on quetiapineCurr Med Res Opin200420561962615140327
   PubMed Web of Science ®Google Scholar
• BuckleyPFEfficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trialsCurr Med Res Opin20042091357136315383183
   PubMed Web of Science ®Google Scholar
• HellewellJSECameron-HandsDCantillonMSeroquel®: evidence for efficacy in the treatment of hostility and aggressionSchizophr Res199829154155
   Web of Science ®Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar
• Seroquel® (quetiapine fumarate) tablets – US prescribing information [updated 2010]. Available from: http://www1.astrazeneca-us.com/pi/seroquel.pdf. Accessed January 18, 2010.
   Google Scholar
• AstraZenecaSeroquel XR (quetiapine fumarate) extended release tablets – US prescribing information [updated 2011 Mar] Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed May 5, 2011.
   Google Scholar
• SuppesTDattoCMinkwitzMNordenhemAWalkerCDarkoDEffectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depressionJ Affect Disord20101211–210611519903574
   PubMed Web of Science ®Google Scholar
• PeuskensJTrivediJKMalyarovSPrevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized placebo-controlled trial in clinically stable patientsPsychiatry (Edgemont)20074113450
   PubMedGoogle Scholar
• Seroquel XR (quetiapine fumarate) Extended-Release Tablets – US prescribing information [updated 2010]. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed April 23, 2010.
   Google Scholar
• AstraZenecaSeroquel XR – Summary of product characteristics [updated 2010] Available from: http://www.medicines.ie/medicine/13032/SPC/Seroquel+XR+50mg%2c+200mg%2c+300mg%2c+400mg+prolonged-release+tablets/. Accessed March 5, 2010.
   Google Scholar
• AstraZenecaSeroquel XR and seroquel approved in europe for prevention of recurrence of bipolar disorder [updated 2009] Available from: http://www.astrazeneca.com/media/latest-press-releases/2009/Seroquel_Bipolar_Maint_EU?itemId=7082393. Accessed January 21, 2010.
   Google Scholar
• El-KhaliliNJoyceMAtkinsonSExtended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled studyInt J Neuropsychopharmacol201013791793220175941
   PubMed Web of Science ®Google Scholar
• BortnickBEl-KhaliliNBanovMEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized studyJ Affect Disord20111281–2839420691481
   PubMed Web of Science ®Google Scholar
• BauerMPretoriusHWConstantELEarleyWRSzamosiJBrecherMExtended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind studyJ Clin Psychiatry200970454054919358791
   PubMed Web of Science ®Google Scholar
• CutlerAJMontgomerySAFeifelDLazarusAÅströmMBrecherMExtended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled studyJ Clin Psychiatry200970452653919358790
   PubMed Web of Science ®Google Scholar
• WeislerRJoyceMMcGillLLazarusASzamosiJErikssonHExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyCNS Spectr200914629931319668121
   PubMed Web of Science ®Google Scholar
• KatzmanMABrawman-MintzerOReyesEBOlaussonBLiuSErikssonHExtended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialInt Clin Psychopharmacol2011261112420881846
   PubMed Web of Science ®Google Scholar
• MeridethCCutlerANeijberASheFErikssonHAEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder (GAD)Eur Neuropsychopharmacol200818S499
   Web of Science ®Google Scholar
• BandelowBChouinardGBobesJExtended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled studyInt J Neuropsychopharmacol20101330532019691907
   PubMed Web of Science ®Google Scholar
• KhanAJoyceMAtkinsonSEggensIBaldytchevaIErikssonHA randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorderJ Clin Psychopharmacol20113141842821694613
   PubMed Web of Science ®Google Scholar
• AstraZenecaSeroquel XR recommended for approval in EU as an add-on treatment of major depressive disorder [updated 2010] Available from: http://www.astrazeneca.com/media/latest-press-releases/seroquelXR-MDD?itemId=9260911. Accessed April 23, 2010.
   Google Scholar
• AstraZenecaUS FDA approves seroquel XR for add-on treatment of major depressive disorder [updated 2009] Available from AstraZeneca. Accessed January 21, 2010.
   Google Scholar
• FigueroaCBrecherMHamer-MaanssonJEWinterHPharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate releaseProg Neuropsychopharmacol Biol Psychiatry200933219920418948162
   PubMed Web of Science ®Google Scholar
• DeVaneCLNemeroffCBClinical pharmacokinetics of quetiapine: an atypical antipsychoticClin Pharmacokinet200140750952211510628
   PubMed Web of Science ®Google Scholar
• NemeroffCBKinkeadBGoldsteinJQuetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosingJ Clin Psychiatry200263Suppl 1351112562141
   PubMed Web of Science ®Google Scholar
• DattoCBerggrenLPatelJErikssonHASelf-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjectsClin Ther20093149250219393840
   PubMed Web of Science ®Google Scholar
• JuckelGWinterHRStåhleLMillerFStridSThe pharmacokinetics of extended release quetiapine fumarate are not affected by a light mealPoster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar DisordersMontreux, SwitzerlandFebruary 3–72008
   Google Scholar
• GoldsteinJMChristophGGrimmSLiuJWidzowskiDBrecherMQuetiapine’s antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptorsEur Neuropsychopharmacol200717Suppl 4S401
   Web of Science ®Google Scholar
• SeemanPAtypical antipsychotics: mechanism of actionCan J Psychiatry2002471273811873706
   PubMed Web of Science ®Google Scholar
• RothBLShefflerDPotkinSGAtypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?Clin Neurosci Res20033108117
   Web of Science ®Google Scholar
• KapurSSeemanPAntipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic actionJ Psychiatry Neurosci200025216116610740989
   PubMed Web of Science ®Google Scholar
• NybergSZukinSPET-measured occupancy of the D2 receptor: a comparison of quetiapine fumarate immediate- and extended-release formulations in healthy subjectsPoster presented at the 48th Annual Meeting of the American College of NeuropsychopharmacologyHollywood, Florida, USADecember 6–10, 2009
   Google Scholar
• NybergSWidzowskiDTranslational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic propertiesEur Psychiatry2010251446
   Web of Science ®Google Scholar
• NybergSTakanoAGrimmSPET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primatesEur Neuropsychopharmacol200717Suppl 4S254S255
   Web of Science ®Google Scholar
• JensenNHRodriguizRMCaronMGWetselWCRothmanRBRothBLN-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine’s antidepressant activityNeuropsychopharmacology200833102303231218059438
   PubMed Web of Science ®Google Scholar
• MamoDCUchidaHVitcuIQuetiapine extended-release versus immediate-release formulation: a positron emission tomography studyJ Clin Psychiatry2008691818618312041
   PubMed Web of Science ®Google Scholar
• PillaiATerryAVJrMahadikSPDifferential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampusSchizophr Res20068219510616442781
   PubMed Web of Science ®Google Scholar
• FumagalliFMolteniRBedogniFQuetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801NeuroReport200415132109211215486491
   PubMed Web of Science ®Google Scholar
• XuHQingHLuWKeeganDRichardsonJSLiX-MNR72: quetiapine attenuates the immobilization-induced decrease of BDNF in rat hippocampusPoster presented at the American Psychiatric AssociationPhiladelphia, Pennsylvania, USAMay 18–23, 2002
   Google Scholar
• GanesanSAgambaramVRandereeFEggensIHuizarKMeulienDSwitching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophreniaCurr Med Res Opin2008241213218021496
   PubMed Web of Science ®Google Scholar
• KahnRSSchulzSCPalazovVDEfficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768683284217592906
   PubMed Web of Science ®Google Scholar
• LindenmayerJPBrownDLiuSBrecherMMeulienDThe efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled studyPsychopharmacol Bull2008413113518779774
   PubMed Web of Science ®Google Scholar
• MollerHJJohnsonSMatevaTEvaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophreniaInt Clin Psychopharmacol20082329510518301124
   PubMed Web of Science ®Google Scholar
• CutlerAJTran-JohnsonTKalaliAAstromMBrecherMMeulienDA failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learnedPsychopharmacol Bull2010434376921240151
   PubMedGoogle Scholar
• KalaliASchulzSCKahnRSEffectiveness of once-daily extended release quetiapine fumarate (quetiapine XR) for excitability, hostility and aggression in schizophreniaPoster 4002 presented at the 161st Annual Meeting of the American Psychiatric AssociationWashington, DC, USAMay 3–8, 2008
   Google Scholar
• LeuchtSBarnesTRKisslingWEngelRRCorrellCKaneJMRelapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trialsAm J Psychiatry200316071209122212832232
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• LeuchtSLasserRThe concepts of remission and recovery in schizophreniaPharmacopsychiatry200639516117016944406
   PubMed Web of Science ®Google Scholar
• PeuskensJTrivediJKBrecherMMillerFLong-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled studyInt Clin Psychopharmacol20102518318720216222
   PubMed Web of Science ®Google Scholar
• MeulienDHuizarKBrecherMSafety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studiesHum Psychopharmacol201025210311520196185
   PubMed Web of Science ®Google Scholar
• BoidiGFerroMRapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open studyHum Psychopharmacol200722529930617487936
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manag Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
   PubMed Web of Science ®Google Scholar
• KnappMKingDPugnerKLapuertaPNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry200418450951615172945
   PubMed Web of Science ®Google Scholar
• GaoKGanocySJGajwaniPMuzinaDJKempDECalabreseJRA review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolenceJ Clin Psychiatry200869230230918211129
   PubMed Web of Science ®Google Scholar
• ConleyRRAscher-SvanumHZhuBFariesDEKinonBJThe burden of depressive symptoms in the long-term treatment of patients with schizophreniaSchizophr Res2007901–318619717110087
   PubMed Web of Science ®Google Scholar
• McElroySLWeislerRHChangWA double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)J Clin Psychiatry201071216317420122366
   PubMed Web of Science ®Google Scholar
• YoungAHMcElroySLBauerMA double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)J Clin Psychiatry201071215016220122369
   PubMed Web of Science ®Google Scholar
• HaroJMNovickDSuarezDAlonsoJLepineJPRatcliffeMRemission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes studyJ Clin Psychopharmacol200626657157817110813
   PubMed Web of Science ®Google Scholar